TERT and neoplasm: There are also interesting alternative strategies such as telomerase vaccination (peptide-based: GV1001; mRNA-based: GRNVAC1) to induce anti-tumor responses or tumor cell lysis through TERT promoter-driven oncolytic adenovirus (Telomelysin (OBP-301)) or TERT promoter-driven pro-apoptotic protein (e.g., TRAIL) to take advantage of high telomerase activity in cancer cells for therapy options.